CARB-X

What CARB-X does

CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) is a global non-profit partnership founded in 2016 and hosted at Boston University School of Law that accelerates the development of antibacterial products targeting drug-resistant bacteria. The organization funds and supports small-to-medium biotech companies and academic institutions developing therapeutics (traditional antibiotics, non-traditional agents such as CRISPR-based bacteriophage therapeutics and engineered peptides), preventatives (vaccines for Neisseria gonorrhoeae, Staphylococcus aureus, Klebsiella pneumoniae), and rapid diagnostics for life-threatening bacterial infections. Its portfolio comprises 123 projects across 14 countries, with $506 million invested since inception, 24 human clinical trials in progress, and 3 diagnostics available. Core offerings include non-dilutive funding programs, Portfolio Acceleration Tools (PATs) such as nephrotoxicity prediction models, susceptibility testing panels (3,000 isolates from 67 countries), and a curated genomic database of nearly 7,000 bacterial isolates, plus R&D Core support, dedicated Company Support Teams, Clinical Advisory Board oversight, and free preclinical services through NIAID partnership.

CARB-X operates a competitive three-stage application process (Expression of Interest → confidential proposal → Advisory Board presentation) with final decisions made by an Investment Committee; recipients must contribute cost share and demonstrate prior private investment. Funded companies receive scientific, regulatory, and business development support including access to the CARB-X Product Developer Conference and Investor Day. The organization's revenue model is grant-based rather than commercial: it does not sell products and does not take equity in portfolio companies. Funding flows from a consortium of government agencies and foundations including BARDA (US Department of Health and Human Services), Wellcome, Germany's BMFTR, UK's DHSC/GAMRIF, the Gates Foundation, the Novo Nordisk Foundation, the Public Health Agency of Canada, Italy's MEF, Japan's MHLW, the European Commission's DG HERA (managed by KfW), and NIAID (providing in-kind preclinical services). The Joint Oversight Board comprises representatives of these funding organizations and sets overall portfolio strategy.

CARB-X extends its reach through a Global Accelerator Network comprising C-CAMP (India), DZIF (Germany), and ILSE (USA), which provide localized scientific, technical, and business support to portfolio companies. The organization addresses a documented market failure in antibiotic development — the last new class of antibiotics for Gram-negative bacteria was discovered in 1962, and many antibiotic companies have filed for bankruptcy — by filling the "Valley of Death" funding gap between basic research and first-in-human clinical trials. Notable portfolio companies include AdJane (gonorrhea vaccine), Centauri Therapeutics (ABX-01 broad-spectrum antimicrobial), Seres Therapeutics (SER-155 for bloodstream infections), SNIPR Biome (CRISPR-phage therapeutic), LimmaTech Biologics (LBT-SA7 vaccine), Visby Medical (PCR diagnostics), and Macro Biologics (Amicidin-β for wound infections). CARB-X was recognized with the 2020 Innovating for Impact Partnership Award from the Global Health Technologies Coalition.

Name

CARB-X

Legal name

CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator)

Website

https://carb-x.org

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

CARB-X is a global non-profit partnership founded in 2016 and hosted at Boston University that provides non-dilutive funding, scientific expertise, and business support to biotech developers of antibiotics, preventatives, and rapid diagnostics targeting drug-resistant bacterial infections.

Ownership category

akta.pro rank

Product category

Antimicrobial R&D Acceleration

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG)

akta.pro secondary industries

Regulatory Strategy & IND/NDA/BLA Submissions Support (HLAIALAH), Formulation & Preclinical CMC Support (Nonclinical) (HLAGAFAL), Translational Medicine & Biomarkers (HLAIALAF)

Keywords

• Antibacterial research funding
• Non-dilutive grants
• Antimicrobial resistance programs
• Biotech acceleration services
• Infectious disease R&D

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

1. Non-dilutive Funding: CARB-X provides non-dilutive funding to product developers, meaning companies receive funding without giving up equity. This is critical for small biotech companies that cannot afford traditional venture funding. CARB-X grants are non-dilutive but require product developers to have solid assets that have demonstrated private investment in their project.
2. Comprehensive Support Services: CARB-X provides scientific, regulatory and business support to product developers at no additional cost. This includes access to R&D Core team, Company Support Teams, Clinical Advisory Board, NIAID preclinical services, and business development support through events like CARB-X Product Developer Conference and Investor Day.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels8 records

Core offering

CARB-X provides non-dilutive funding along with scientific, regulatory, and business support to product developers working on antibiotics, preventatives (vaccines), rapid diagnostics, and other life-saving products targeting drug-resistant bacteria. The organization bridges basic research and first-in-human clinical trials, accelerating the world's most scientifically diverse early-development antibacterial pipeline through milestone-based grants and comprehensive acceleration services.

Product overview

CARB-X is a global non-profit partnership that accelerates antibacterial innovation by providing non-dilutive funding, scientific expertise, regulatory guidance, and business support to product developers. The organization does not develop its own commercial product but operates as a funding and support accelerator. Its core offerings include funding programs for early-stage antibacterial research, Portfolio Acceleration Tools (PATs) including nephrotoxicity models and susceptibility testing panels, R&D Core and Company Support Teams for project oversight, Clinical Advisory Board services, preclinical services through NIAID partnerships, market-shaping support, and business development events. CARB-X Connect provides an informational feedback channel for developers. The portfolio supports therapeutics (antibiotics, non-traditional agents), preventatives (vaccines), rapid diagnostics, and other products targeting drug-resistant bacteria.

Differentiator

Problem solved

Functional benefit

Products and services

• CARB-X Funding Programs Non-dilutive funding and comprehensive support package for product developers working on antibiotics, preventatives (vaccines), rapid diagnostics, and other life-saving products to combat drug-resistant bacteria. Awarded through a competitive three-stage application process (Expression of Interest, confidential proposal, Advisory Board presentation) with milestone-based grant disbursements and cost-share requirements. Includes bundled access to R&D Core, Company Support Teams, Clinical Advisory Board, NIAID preclinical services, Portfolio Acceleration Tools, and business development support.

Named customers10 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered supporting.

• Centre for Cellular and Molecular Platforms (C-CAMP)supportingImplementation/ SI/ Consulting PartnerIndia's premier Life Science innovation and entrepreneurship hub. One of the largest life science incubators in the country, providing funding, incubation, acceleration and mentorship to start-ups. An initiative supported by Department of Biotechnology, Ministry of Science and Technology, Government of India, located in Bengaluru.
• German Center for Infection Research (DZIF)supportingImplementation/ SI/ Consulting PartnerWith 35 establishments at 7 sites across Germany, DZIF is specialized in translational infection research developing new diagnostic, preventative and therapeutic methods. Actively engages in AMR research and promotes innovative product development through funding, project management and regulatory support.
• Institute for Life Sciences Entrepreneurship (ILSE)supportingImplementation/ SI/ Consulting PartnerNon-profit organization located on campus of Kean University in Union, New Jersey, USA. Provides incubator space, research and accelerator services to life science companies. Core Research Lab provides research services for small to medium size biotechs. Has CLIA-certified lab on premises.

Scale indicators10 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• GARDP (Global Antibiotic Research & Development Partnership): Geneva-based non-profit that also funds late-stage antibiotic development for drug-resistant infections. Most directly comparable non-profit peer; both are multi-donor accelerators focused on antibacterial innovation and frequently co-receive funding from the same sovereign sources.
• AMR Action Fund: Pharma-backed fund investing in late-stage clinical antibiotic developers. Comparable as a non-dilutive or quasi-non-dilutive capital pool targeting the same AMR pipeline gap, though focused on a later stage than CARB-X.
• Drugs for Neglected Diseases initiative (DNDi): Non-profit product development partnership funding R&D for neglected tropical diseases. Highly comparable operating model — multi-donor funding, non-dilutive grants, integrated scientific and regulatory support — applied to a different therapeutic area.
• Medicines for Malaria Venture (MMV): Geneva-based product development partnership funding antimalarial drug R&D. Closest structural analog: public-private, non-dilutive funding, end-to-end support from discovery through clinical development, focused on a single infectious disease area.
• Foundation for Innovative New Diagnostics (FIND): Geneva-based non-profit accelerating development and delivery of diagnostics for poverty-related diseases. Directly comparable for the rapid diagnostics portion of CARB-X's portfolio, with similar donor base and accelerator-style support.
• REPAIR Impact Fund: Copenhagen-based Novo Nordisk Foundation fund investing in early-stage antibiotic R&D. Overlaps with CARB-X's therapeutic funding focus and shares a common donor (Novo Nordisk Foundation).
• TB Alliance: Non-profit product development partnership accelerating tuberculosis drug R&D. Same accelerator-style operating model and donor architecture as CARB-X but applied to TB.

Broad incumbents

• BARDA (Biomedical Advanced Research and Development Authority): US federal agency funding advanced development of medical countermeasures. As CARB-X's largest single funder, it is a broader institutional player that both supports and partially overlaps with CARB-X's portfolio strategy.
• Wellcome Trust: Major biomedical research funder and co-founder of CARB-X. Comparable mission in infectious disease R&D funding but operates as a much broader science philanthropy, not a focused accelerator.

Emerging players

• Combating Antibiotic-Resistant Biopharmaceutical Accelerator ecosystem participants (e.g., VenatoRx, Entasis): CARB-X graduates and portfolio companies that have advanced to late-stage clinical development. They represent the next stage of the value chain CARB-X feeds and illustrate the kind of investable assets the accelerator produces.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/carb_x
• LinkedInlinkedin.com/company/carb-x

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments129 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CARB-X